Antibody Drug Conjugate Development and Manufacture
Piramal
Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.
Spotlight
  Executives Raise Questions on Clinical Trial Sponsors’ Oversight of CROsTension between clinical trial sponsors and CROs in terms of CRO oversight may not be relieved any... |
Key Industry Events
Most Popular News
Follow us on
Supplier Webinars
On demand Supplier Webinars
All supplier webinars
Technical Papers
- 505(b)(2): It’s A Different Animal
Camargo - A risk assessment framework for donor and recipient companies to jointly analyze and document the technical and business risks associated with the technical transfer of pharmaceutical product
Alkermes - RECIPHARM: WHY CONTINUOUS AUDIT READINESS IS CRUICAL
Recipharm AB - Increasing Accuracy, Not Costs
Mettler Toledo - White Paper: Is My Method Still Valid?
SGS - ePathology Improves Data Accuracy & Study Productivity! – Amicus Study Confirms
Aperio - What Makes 505(b)(2) Different?
Camargo - Vcaps® Plus capsules: The next generation HPMC capsule for optimum formulation of Pharmaceutical Dosage forms
Capsugel - Clinical Trial Logistics in Africa: Ensuring Quality, Compliance and Control within the Pharmaceutical Supply Chain
World Courier
Sponsors involved as well
One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.
Posted by Guillaume Miara
30 August 2011 | 15h30